Hepatitis B cure: Current situation and prospects

Table 1 Studies in which chronic hepatitis B patients were cured after pegylated interferon alpha-based treatment

Treatment option	Ref.	Duration of interferon use	HBsAg negative conversion rate (%)
“NA plus Peg-IFNα” strategy	Marcellin et al[21], 2016	48 wk	9.1
	Hagiwara et al[22], 2018	48 wk	10.4
	Hu et al[23], 2021	48 wk	11.5
“Switching NA to Peg-IFNα” strategy	Han et al[24], 2016	48 wk	8.5
	Wu et al[25], 2019	48 wk	9.3
	Hu et al[26], 2018	48 wk	14.4
“NA plus Peg-IFNα” strategy	Bourlière et al[27], 2017	48 wk	7.8
	Lim et al[28], 2019	48 wk	9.0
	Li et al[29], 2015	48 wk	18.5
	Wu et al[20], 2020	72 wk	37.4
“Peg-IFNα monotherapy” strategy (IHCs)	Cao et al[30], 2017	48 wk	29.8
	Wu et al[31], 2021	72 wk	47.9
	Chen et al[32], 2021	48 wk	55.6
“Extended treatment” strategy	Hu et al[26], 2018	96 wk	20.7
	Li et al[33], 2011	81.32 ± 39.36 wk	21.7
	Yan et al[34], 2018	96 wk	29.0
“Intermittent treatment” strategy	Li et al[35], 2022	/	19.4

HBsAg: Hepatitis B surface antigen; NA: Nucleos(t)ide analog; Peg-IFNα: Pegylated interferon alpha; IHCs: Inactive Hepatitis B surface antigen carrier status.